Overall, disparate expression of mTOR and ERK-1/2 associated signaling proteins can be selectively targeted along with mTOR or ERK-1/2 inhibitors to efficiently inhibit the tumor growth, metastasis, and to increase the overall survival depending upon the specific race. Here, MAPK3 is linked to neoplasm.